Clinical Trial Update: Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

View source ↗

Summary

This update reports on the safety profile of BGF MDI in Chinese patients with chronic obstructive pulmonary disease based on a completed trial in routine clinic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BGF MDI (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Status: COMPLETED